Author:
Banfor Patricia N,Franklin Pamela A,Segreti Jason A,Widomski Deborah L,Davidsen Steven K,Albert Daniel H,Cox Bryan F,Fryer Ryan M,Gintant Gary A
Publisher
Ovid Technologies (Wolters Kluwer Health)
Subject
Cardiology and Cardiovascular Medicine,Pharmacology
Reference19 articles.
1. Discovery of N-(4-(3-amino-1H-indazol-4-yl)phenyl)-N-(2-fluoro-5-methylphenyl)urea (ABT-869), a 3-aminoindazole-based orally active multitargeted receptor tyrosine kinase inhibitor.;Dai;J Med Chem,2007
2. The angiotensin-I-converting enzyme inhibitor perindopril suppresses tumor growth and angiogenesis: possible role of the vascular endothelial growth factor.;Yoshiji;Clin Cancer Res,2001
3. Phase I clinical study of AZD2171, an oral vascular endothelial growth factor signaling inhibitor, in patients with advanced solid tumors.;Drevs;J Clin Oncol,2007
4. AZD2171: a highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancer.;Wedge;Cancer Res,2005
5. Differential requirement of a motif within the carboxyl-terminal domain of alpha-platelet-derived growth factor (alpha PDGF) receptor for PDGF focus forming activity chemotaxis, or growth.;Yu;J Biol Chem,1995
Cited by
38 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献